Supporting Grifols
Pioneering Therapeutic Proteins for Life-Saving Treatments

Therapeutic protein products from human plasma are crucial for treating life-threatening conditions, often without alternative remedies, with strict safety measures to prevent blood-borne infections.

These safety measures include Stringent Donor Screening, PCR Testing of Plasma, Fractionation and Dual specific Viral Inactivation Steps. Grifols has been a key player in introducing innovative therapies in Ireland and worldwide.

• Flebogamma DIF (previously Alphaglobin), the first liquid ready to use, pasteurised intravenous immunoglobulin in 1996

• Prolastin, the first Alpha 1 Protease Inhibitor approved in Ireland in January 2007

• Pedigri is the only online access portal that enables healthcare professionals to access information related to each donation, specific information for each product lot, and the current product SPC/package insert .